PDF herunterladen
Thromb Haemost 1978; 40(02): 486-498
DOI: 10.1055/s-0038-1648682
Original Article
Schattauer GmbH Stuttgart

An Assay of the Antithrombotic Action of Warfarin: Its Correlation with the Inhibition of Stasis Thrombosis in Rabbits

Stanford Wessler
The Department of Medicine, New York University School of Medicine, New York, New York 10016 and Tel Hashomer Hospital, Tel Aviv, Israel
,
Sanford N Gitel
The Department of Medicine, New York University School of Medicine, New York, New York 10016 and Tel Hashomer Hospital, Tel Aviv, Israel
,
Harry Bank
The Department of Medicine, New York University School of Medicine, New York, New York 10016 and Tel Hashomer Hospital, Tel Aviv, Israel
,
Uri Martinowitz
The Department of Medicine, New York University School of Medicine, New York, New York 10016 and Tel Hashomer Hospital, Tel Aviv, Israel
,
Ronald C Stephenson
The Department of Medicine, New York University School of Medicine, New York, New York 10016 and Tel Hashomer Hospital, Tel Aviv, Israel
› Institutsangaben
Weitere Informationen

Publikationsverlauf

Received 01. März 1978

Accepted 18. April 1978

Publikationsdatum:
12. Juli 2018 (online)

Auch verfügbar auf
  als PDF herunterladen  Lizenzen und Reprints

Summary

No assay of the antithrombotic action of warfarin has been available. Experiments were performed to determine whether Xa inhibitory activity - the reaction rate between activated factor X (Xa) and antithrombin III - could serve this function. 105 warfarin-treated patients demonstrated a significant 18% increase in Xa inhibitory activity compared to 51 controls, p <0.001, without any correlation between this activity and the prothrombin times in the treated patients. A similar increase in Xa inhibitory activity was obtained in rabbits treated with 2 mg of warfarin per day compared to control animals, p <0.001. Employing an assay which routinely produced venous thrombosis after clotting proteases were infused into warfarin-treated and control rabbits, three observations were made. 1. The extent of stasis thrombosis induced by injection of thrombin, Xa or activated factor IX, was significantly reduced in warfarin-treated rabbits compared to control animals, independent of alteration in the four established vitamin K-dependent zymogens. 2. In the rabbit, significant changes in prothrombin times and prothrombin and factor X activities preceded by 5 days both the increase in Xa inhibitory activity and the antithrombotic effect which became significant on the sixth day. 3. The correlation between Xa inhibitory activity of warfarin-treated rabbits and the extent of stasis thrombosis induced by Xa was significant, p<0.05. Xa inhibitory activity is one measure of the antithrombotic action of warfarin.

 

  • References

  • 1 Abildgaard U, Fagerhol MK, Egeberg O. 1970; Comparison of progressive antithrombin activity and the concentration of 3 thrombin inhibitors in human plasma. Scandinavian Journal of Clinical and Laboratory Investigation 26: 349
    CrossrefPubMedSuche in Google Scholar
  • 2 Alexander B, Colman R. 1960; Evidence for a new serum thromboplastic factor. Thrombosis et Diathesis Haemorrhagica (Suppl.) 4: 66
    PubMedSuche in Google Scholar
  • 3 Bachmann F, Duckert F, Roller F. 1958; The Stuart-Prower factor assay and its clinical significance. Thrombosis et Diathesis Haemorrhagica 2: 24
    PubMedSuche in Google Scholar
  • 4 Biggs R, Denson KW E, Akman R, Borrett R, Hadden M. 1970; Antithrombin III, antifactor Xa and heparin. British Journal of Haemotology 19: 283
    PubMedSuche in Google Scholar
  • 5 Boxer GJ, Bang NU, Ferroni JW, Benson MD. 1977; Plasma amyloid P-component inhibits heparin activity. Blood Suppl (Suppl. 01) 50: 260
    PubMedSuche in Google Scholar
  • 6 Breckenridge A. 1978; Oral anticoagulant drugs: Pharmacokinetic aspects. Seminars in Hematology 15: 19
    PubMedSuche in Google Scholar
  • 7 Carlisle TL, Shah DV, Schlegel R, Suttie JW. 1975; Plasma abnormal prothrombin and microsomal prothrombin in various species. Proceedings of the Society of Experimental Biology and Medicine 148: 140
    PubMedSuche in Google Scholar
  • 8 Coon WW, Willis III PW. 1972; Thromboembolic complications during anticoagulant therapy. Archives of Surgery 105: 209
    CrossrefPubMedSuche in Google Scholar
  • 9 Davis BJ. 1964; Disc electrophoresis-II: Method and application to human serum proteins. Annals of New York Academy of Science 121: 404
    PubMedSuche in Google Scholar
  • 10 Discipio RG, Hermodson MA, Yates SG, Davie EW. 1977; A comparison of human prothrombin Factor IX (Christmas factor), Factor X (Stuart factor), and protein S. Biochemistry 16: 698
    CrossrefPubMedSuche in Google Scholar
  • 11 Domenet JG, Evans DW, Stephenson H. 1966; Anticoagulants in congestive heart failure. British Medical Journal 4: 866
    PubMedSuche in Google Scholar
  • 12 Gitel SN, Stephenson RC, Wessler S. 1977; a In vitro and in vivo correlation of clotting protease activity: Effect of heparin Proceedings of the. National Academy of Sciences (USA) 74: 3028
    CrossrefPubMedSuche in Google Scholar
  • 13 Gitel SN, Stephenson RC, Wessler S. 1978; The activated factor X-antithrombin III reaction rate: A measure of the increased thrombotic tendency induced by estrogen-containing oral contraceptives in rabbits. Haemostasis 7: 10
    PubMedSuche in Google Scholar
  • 14 Gitel SN, Wessler S. 1975; Plasma antithrombin III: A quantitative assay of biological activity. Thrombosis Research 7: 5
    CrossrefPubMedSuche in Google Scholar
  • 15 Gitel SN, Wessler S, Medina VM. 1977; b The rabbit as an animal model for the activated factor X-antithrombin III-heparin reaction. Circulation Research 41: 187
    CrossrefPubMedSuche in Google Scholar
  • 16 Henstell HH, Kugerman M. 1967; The nature of heparin antithrombin action. Thrombosis et Diathesis Haemorrhagica 18: 167
    PubMedSuche in Google Scholar
  • 17 Hjort P, Rappaport SL, Owren PA. 1955; A simple, specific one-stage prothrombin assay using Russell’s viper venom in cephalin suspension. Journal of Laboratory and Clinical Medicine 46: 89
    PubMedSuche in Google Scholar
  • 18 Hurn M, Barker NW, Mann FD. 1947; Variations in prothrombin and antithrombin following the administration of Dicumarol. American Journal of Clinical Pathology 17: 111
    PubMedSuche in Google Scholar
  • 19 Kisiel W, Ericsson LH, Davie EW. 1976; Proteolytic activation of protein C from bovine plasma. Biochemistry 15: 4893
    CrossrefPubMedSuche in Google Scholar
  • 20 Roller F. 1959. What is the present status of Factor X. In: Brinkhous KM. (ed) Hemophilia and Other Hemorrhagic. States University of North Carolina Press; Chapel Hill: p 231
    Suche in Google Scholar
  • 21 Krenkel JK. 1969; Introduction: symposium on the choice of animal models for the study of disease processes in man. Federation Proceedings 28: 160
    PubMedSuche in Google Scholar
  • 22 Laemmli UK. 1970; Cleavage of the structural proteins during the assembly of the head of bacteriophage T4. Nature 227: 680
    CrossrefPubMedSuche in Google Scholar
  • 23 Magnusson S, Sottrup-Jensen L, Peterson TE. 1974; Primary structure of the vitamin K-dependent part of prothrombin. FEBS Letters 44: 189
    CrossrefPubMedSuche in Google Scholar
  • 24 Nelsestuen GL, Zytkovicz TH, Howard JB. 1974; The mode of action of vitamin K: Identification of y-carboxyglutamic acid as a component of prothrombin. Journal of Biological Chemistry 249: 6347
    PubMedSuche in Google Scholar
  • 25 Ødegard OR, Teien AN. 1976; Antithrombin III, heparin cofactor and antifactor Xa in a clinical material. Thrombosis Research 8: 173
    CrossrefPubMedSuche in Google Scholar
  • 26 Quick AJ. 1937; The coagulation defect in the sweet clover disease and the hemorrhagic chick disease of dietary origin. A consideration of the source of prothrombin American Journal of Physiology 118: 260
    PubMedSuche in Google Scholar
  • 27 Rosenberg RD. 1977; Chemistry of the hemostatic mechanism and its relationship to the action of heparin. Federation Proceedings 36: 10
    PubMedSuche in Google Scholar
  • 28 Sagar S, Stamatahs JD, Higgins AF, Nairn D, Maffei FH, Thomas DP, Kakkar VV. 1976; a Efficacy of low-dose heparin in prevention of extensive deep-vein thrombosis in patients undergoing total-hip replacement. Lancet 1: 1151
    PubMedSuche in Google Scholar
  • 29 Sagar S, Stamatakis JD, Thomas DP, Kakkar VV. 1976; b Oral contraceptives, antithrombin III activity, and postoperative deep vein thrombosis. Lancet 2: 509
    PubMedSuche in Google Scholar
  • 30 Seegers WH. 1968; Antithrombin as proteinase inhibitor. Annals of the New York Academy of Science 146: 593
    CrossrefPubMedSuche in Google Scholar
  • 31 Spaet TH. 1959. The present status of Factor X. In: Brinkhous KM. (ed) Hemophilia and Other Hemorrhagic. States University of North Carolina Press; Chapel Hill: p 240
    Suche in Google Scholar
  • 32 Stenflo J. 1976; A new vitamin K-dependent protein: purification from bovine plasma and preliminary characterization. Journal of Biological Chemistry 251: 355
    PubMedSuche in Google Scholar
  • 33 Stenflo J, Fernlund P, Egan W, Roefstroff P. 1974; Vitamin K-dependent modifications of glutamic acid residues in prothrombin. Proceedings of the National Academy of Sciences (USA) 71: 2730
    CrossrefPubMedSuche in Google Scholar
  • 34 Stenflo J, Suthe JW. 1977. Vitamin K-dependent formation of γ-carboxyglutamic acid. In: Snell EE, Boyer PD, Meister A, Richardson CC. (eds) Annual Reviews of Biochemistry. Annual Reviews Inc; Palo Alto, CA: p 157
    Suche in Google Scholar
  • 35 Sutoe JW, Jackson CM. 1977; Prothrombin structure, activation, and biosynthesis. Physiological Reviews 57: 1
    CrossrefPubMedSuche in Google Scholar
  • 36 Wessler S, Ballon JD, Katz JH. 1957; Studies in intravascular coagulation: V. A distinction between the anticoagulant and antithrombotic effects of Dicumarol. New England Journal of Medicine 256: 1223
    CrossrefPubMedSuche in Google Scholar
  • 37 Wessler S, Gitel SN. 1975. Biochemical rationale for low-dose heparin in deep venous thrombosis. In: Fratantoni J, Wessler S. (eds) Prophylactic Therapy for Deep Venous Thrombosis and Pulmonary Embolism. U S Government Printing Office; Washington, D C: p 177
    Suche in Google Scholar
  • 38 Wessler S, Gitel SN, Wan LS, Pasternack BS. 1976; Estrogen-containing oral contraceptive agents: A basis for their thrombogenicity. Journal of the American Medical Association 236: 2179
    CrossrefPubMedSuche in Google Scholar
  • 39 Wessler S, Reimer SM, Sheps MC. 1959; Biologic assay of thrombosis-inducing activity in human serum. Journal of Applied Physiology 14: 943
    CrossrefPubMedSuche in Google Scholar
  • 40 Wilcoxon F. 1947; Probability tables for individual comparisons in ranking methods. Biometrics 3: 119
    CrossrefPubMedSuche in Google Scholar
  • 41 Witte S, Dirnberger P. 1955; Die Antithromboischen Gerinnungsfaktoren bei Thrombosekrankheiten. Deutsches Archiv fur Klinische Medizin 202: 184
    PubMedSuche in Google Scholar
  • 42 Yin ET, Eisenkramer L, Butler JV. 1975. Heparin interaction with activated Factor X and its inhibitor. In: Bradshaw RA, Wessler S. (eds) Heparin: Structure, Function and Clinical Implications. Plenum Press; New York: p 239
    Suche in Google Scholar
  • 43 Yin ET, Wessler S. 1968; Bovine thrombin and activated Factor X: Separation and purification. Journal of Biological Chemistry 243: 112
    PubMedSuche in Google Scholar
  • 44 Yin ET, Wessler S, Stoll PJ. 1971; a Identity of plasma activated Factor X inhibitor with antithrombin III and heparin cofactor. Journal of Biological Chemistry 246: 3712
    PubMedSuche in Google Scholar
  • 45 Yin ET, Wessler S, Stoll PJ. 1971; b Biological properties of the naturally occurring plasma inhibitor to activated Factor X. Journal of Biological Chemistry 246: 3703
    PubMedSuche in Google Scholar
  • 46 Zytkovicz TH, Nelsestuen GL. 1975; 3H Diborane reduction of vitamin K-dependent calcium-binding proteins: Identification of a unique amino acid. Journal of Biological Chemistry 250: 2968
    PubMedSuche in Google Scholar